Scribe Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$100M | 1 yr ago

About Scribe Therapeutics

Scribe Therapeutics focuses on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.

Scribe Therapeutics Headquarter Location

1150 Marina Village Pkwy

Alameda, California, 94501,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Scribe Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Scribe Therapeutics is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Scribe Therapeutics Patents

Scribe Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Autosomal dominant disorders
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics



Rare diseases, Cerebrum, Syndromes, Autosomal dominant disorders, Transcription factors


Application Date


Grant Date


Related Topics

Rare diseases, Cerebrum, Syndromes, Autosomal dominant disorders, Transcription factors



Latest Scribe Therapeutics News

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

May 12, 2022

CEO Benjamin Oakes discusses his company’s progress toward developing genome editing treatments A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies have made progress beyond the little that they have announced publicly. Scribe disclosed last week that Biogen had exercised an option for a second target through which they aim to treat disease [Scribe Therapeutics] Share Headquartered in Alameda, CA, Scribe develops CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies in therapeutic areas that include neurodegenerative diseases; ophthalmological diseases; multi-system, muscle, and metabolic disorders; and hematopoietic disorders. That platform aims to address safety, delivery, poor editing outcomes, and the long-running bitter legal battle over who invented CRISPR-Cas9. To avoid intellectual property uncertainty, Scribe has engineered its own CRISPR effectors . . . See More on the Edge Continue reading this article and more with a GEN Edge subscription

Scribe Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Scribe Therapeutics Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.